新诊断前列腺癌患者中18F-PSMA-1007与18F-DCFPyL PET/CT的前瞻性个体内比较:一项先导研究
12例未用药或术前前列腺癌患者相隔48小时分别接受约250 MBq的18F-DCFPyL与18F-PSMA-1007,注射后2小时在同一PET/CT扫描仪上以相同重建算法成像。两种示踪剂均检出全部12例患者的PSMA阳性病灶且检出病灶相同,肿瘤SUVmax无统计学显著差异;正常器官分布存在差异,18F-DCFPyL在肾、膀胱、泪腺摄取显著更高,18F-PSMA-1007在肌肉、下颌下腺、舌下腺、脾、胰腺、肝、胆囊摄取显著更高。
要点
- 12例患者中两种示踪剂均检出PSMA阳性病灶且检出病灶相同。
- 局部肿瘤、淋巴结转移、骨转移的SUVmax在两种示踪剂间无统计学显著差异。
- 18F-PSMA-1007非泌尿排泄可能有利于局部复发或盆腔淋巴结转移显示。
核心结论
- 18F-DCFPyL与18F-PSMA-1007均获得优异成像质量,在所评估的常规情况下临床所见相同。
- 18F-PSMA-1007的非泌尿排泄对部分患者局部复发或盆腔淋巴结转移的勾画可能有一定优势。
- 18F-DCFPyL较低的肝脏本底可能在晚期出现罕见肝转移时更有利。
研究设计与样本
- 前瞻性个体内比较的先导研究,纳入12例未用药或术前的新诊断前列腺癌患者。
主要发现
- 12例患者中12例检出PSMA阳性病灶,18F-DCFPyL与18F-PSMA-1007检出的病灶相同。
- 局部肿瘤、淋巴结转移和骨转移的SUVmax在18F-DCFPyL与18F-PSMA-1007间无统计学显著差异。
- 18F-DCFPyL在肾、膀胱和泪腺的摄取显著更高。
- 18F-PSMA-1007在肌肉、下颌下腺、舌下腺、脾、胰腺、肝和胆囊的摄取显著更高。
关键数值与推荐
- 两种示踪剂给药活度均约为250 MBq,相隔48小时给药,注射后2小时成像。
- 成像使用同一PET/CT扫描仪和相同重建算法。
临床怎么用
- 两种示踪剂在所评估的常规情况下产生相同的临床所见。
- 作者认为18F-PSMA-1007的非泌尿排泄对部分患者局部复发或盆腔淋巴结转移的勾画可能有一定优势。
- 作者认为18F-DCFPyL较低的肝脏本底在晚期出现罕见肝转移时可能更有利。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The introduction of 18F-labeled prostate-specific membrane antigen (PSMA)-targeted PET/CT tracers, first 18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid) and more recently 18F-PSMA-1007 (((3S,10S,14S)-1-(4-(((S)-4-carboxy-2-((S)-4-carboxy-2-(6-18F-fluoronicotinamido)butanamido)butanamido)methyl)phenyl)-3-(naphthalen-2-ylmethyl)-1,4,12-trioxo-2,5,11,13-tetraazahexadecane-10,14,16-tricarboxylic acid)), have demonstrated promising results for the diagnostic workup of prostate cancer. This clinical study presents an intraindividual comparison to evaluate tracer-specific characteristics of 18F-DCFPyL versus 18F-PSMA-1007. Methods: Twelve prostate cancer patients, drug-naïve or before surgery, received similar activities of about 250 MBq of 18F-DCFPyL and 18F-PSMA-1007 48 h apart and were imaged 2 h after injection on the same PET/CT scanner using the same reconstruction algorithm. Normal-organ biodistribution and tumor uptake were quantified using SUVmaxResults: PSMA-positive lesions were detected in 12 of 12 prostate cancer patients. Both tracers, 18F-DCFPyL and 18F-PSMA-1007, detected the same lesions. No statistical significance could be observed when comparing the SUVmax of 18F-DCFPyL and 18F-PSMA-1007 for local tumor, lymph node metastases, and bone metastases. With regard to normal organs, 18F-DCFPyL had statistically significant higher uptake in kidneys, urinary bladder, and lacrimal gland. Vice versa, significantly higher uptake of 18F-PSMA-1007 in muscle, submandibular and sublingual gland, spleen, pancreas, liver, and gallbladder was observed. Conclusion: Excellent imaging quality was achieved with both 18F-DCFPyL and 18F-PSMA-1007, resulting in identical clinical findings for the evaluated routine situations. Nonurinary excretion of 18F-PSMA-1007 might present some advantage with regard to delineation of local recurrence or pelvic lymph node metastasis in selected patients; the lower hepatic background might favor 18F-DCFPyL in late stages, when rare cases of liver metastases can occur.
引用
- Giesel FL, Will L, Lawal I, et al. Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study. J Nucl Med. 2017. PMID: 29269569. doi:10.2967/jnumed.117.204669
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。